Menu
← Oncology Approval Tracker
FDA DECISION ·
Regorafenib (Stivarga reference)
regorafenib · Teva Pharmaceuticals USA
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First generic tablets; FDA highlights use in metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, anti-VEGF treatment, and anti-EGFR therapy if RAS wild type.
LAMPGEN ANALYSIS
Why it matters
A first generic can widen sourcing options for oral regorafenib in previously treated colorectal cancer.
What research teams should watch
Track the dispensing product and preserve toxicity monitoring and adherence counseling when the supplier changes.
PRIMARY RECORDS